VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
QGEN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
QGENQiagen N.V.
$39.41$8.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksQGENCash Flow

Qiagen N.V. (QGEN) Cash Flow Statement

30Y historyFree accessUpdated daily

Earnings quality remains high with an OCF/NI ratio of 1.48, though free cash flow margins have contracted to 10.9% amid aggressive $496.7 million share repurchases.

QGEN Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations615.22M654.33M673.55M459.45M715.26M639M492.27M330.84M359.5M286.78M341.6M317.5M287.96M258.96M244.88M244.78M250.75M217M173M84.81M101.48M91.24M53.8M64.06M36.69M58.09M38.87M26.18M11.6M8.5M4.1M
Operating CF Margin %-31.31%34.05%23.38%33.4%28.38%26.32%21.67%23.94%20.23%25.53%24.79%21.41%19.89%19.52%20.93%23.06%21.49%19.37%13.05%21.79%22.9%14.13%18.23%12.29%22.02%19.05%18.18%10.53%11.44%7.56%
Operating CF Growth %-42.36%-2.85%46.6%-35.76%11.93%29.81%48.79%-7.97%25.36%-16.05%7.59%10.26%11.2%5.75%0.04%-2.38%15.56%25.43%103.98%-16.43%11.23%69.59%-16.02%74.62%-36.84%49.43%48.5%125.66%36.47%107.32%5.13%
Net Income402.17M424.88M83.59M341.3M423.21M512.6M73.64M-41.45M190.38M40.39M80.3M126.86M117.2M69.1M129.54M94.95M144.31M137.77M89.03M50.12M70.54M62.23M48.7M42.85M23.14M34.42M20.11M12.62M12.4M8.8M5.3M
Depreciation & Amortization202.28M193.75M203.27M205.34M208.4M214.93M209.97M231.46M206.44M216.45M213.06M191.47M200.78M199.35M197.89M167.38M142.78M120.39M105.7M62.58M30.04M24.95M22.96M25.79M24.71M15.06M10.46M7.83M5.8M4.9M2.5M
Stock-Based Compensation47.71M50.4M43.63M47.1M49.51M38.39M40.94M65.89M40.11M34.44M28.29M27.57M42.19M37.94M25.36M19.54M13.59M9.75M9.79M8.98B326M0000000000
Deferred Taxes-23M-20.07M-23.04M10.73M-9.6M-5.29M-14.26M-55.36M-23.27M39.55M-65.97M-37.19M-41.29M-68.09M-22.77M-31.86M-19.94M-10.61M-17.69M-1.65M5.21M-2.2M-10.47M12.18M5.03M-1.79M-5.38M-1.53M-1M-900K400K
Other Non-Cash Items48.11M39.88M230.65M41.94M75.63M8.38M165.18M174.63M41M23.18M75.64M89.91M47.89M14.99M-1.27M37.69M-14.09M-5.51M4.24M-8.95B-325.23M10.01M12.62M8.38M-1.88M16.25M25.66M6.24M100K400K100K
Working Capital Changes-62.05M-34.51M135.45M-186.96M-31.88M-130.01M16.8M-44.32M-95.16M-67.23M10.29M-81.11M-78.81M5.67M-83.87M-42.92M-15.9M-34.8M-18.07M-55.83M-5.08M-3.75M-20.01M-25.14M-14.31M-5.85M-11.97M1.02M-6.3M-4.7M-4.2M
Change in Receivables-45.06M-36.39M12.22M-55.12M15.45M-7.4M-14.71M-39.58M-41.81M-34.16M-12.24M-24.76M-16.56M-14.92M-14.29M-28.2M-6.88M-25.21M-19.08M1.81B378M54M128M1.75B631M000000
Change in Inventory-20.19M-848K87.75M-44.79M-61.95M-81.8M-107.57M-30.03M-36.92M-21.63M-20.35M-33.19M-41.79M-17.5M-20.38M-15.95M2.35M-21.53M-30.37M-8.74M-4.2M3.76M2.02M-6.4M-18.18M-3.93M-6.59M-3.7M-3.2M-6M-4.2M
Change in Payables5.26M-8.42M1.45M-22.42M-1.76M-5.97M8.44M9.25M6.99M4.32M-1.47M7.73M-5.5M-6.79M-9.95M7.26M3.48M-9.08M5.75M956M2.72B-4.71B599M-6.61B-424M000000
Cash from Investing-213.89M-305.28M-249.23M-87.66M-726.76M-202.43M-453.29M-222.28M-211.36M-464.26M-179.06M-146.2M-407.6M-251.74M-300.89M-540.32M-215.51M-341.74M-210.52M-659.67M-165.47M-98.5M-51.15M-14.06M-64.79M-90.8M-45.03M-23.73M-11.7M-5.9M-38.3M
Capital Expenditures-210.7M-207.13M-167.17M-162.8M-149.34M-206.53M-304.24M-274.88M-150.76M-124.41M-93.92M-117.48M-97M-118.69M-128.09M-121.39M-123.91M-69.36M-57.92M-58.61M-35.35M-13.73M-12.62M-19.56M-59.14M-102.07M-39.45M-11.81M-10.5M-6.8M-9.7M
CapEx % of Revenue10.04%9.91%8.45%8.28%6.97%9.17%16.27%18.01%10.04%8.78%7.02%9.17%7.21%9.12%10.21%10.38%11.39%6.87%6.49%9.02%7.59%3.45%3.32%5.57%19.8%38.7%19.33%8.2%9.53%9.15%17.9%
Acquisitions-224.63M-291.23M0-149.53M-63.65M-16.63M-239.57M-67.06M-172.83M-50.55M-90.49M-66.93M-160.44M-170.55M-132M-457.48M-36.98M-234.73M-150.53M-859.69M-95.38M-82M17.67M1.79M-14.06M274K385K98K000
Investments-------------------------------
Other Investing-135.34M-32.16M21.35M-66.55M-9.77M61.47M-66.57M22.7M-2.13M-22.98M-8.74M-5.88M3.64M-977K1.31M2.02M3.47M869K-208K5.82M1.91M-17.76M-33.1M-2.78M-2.37M-2.32M-817K-32K-2.6M-1M-500K
Cash from Financing-395.93M-178.98M-422.9M-433.83M-125.8M-150.37M-74.32M-639.08M360.41M387.19M-10.6M-258.61M192.84M-68.76M226.6M-310.63M-35.23M629.2M12.77M494.05M303.16M2.96M95.62M-1.88M6.12M66.25M14.84M3.6M1.8M3.2M31.9M
Debt Issued (Net)208.15M208.15M-107.33M-436.76M-108.55M-41.34M-35.55M-505.43M493.57M722.86M-8.06M-252.95M325.34M-6.49M249.22M-429.56M-50.25M-27.99M-5M440.23M284.45M-5.46M90.49M-4M3.79M58.56M-5.92M1.72M714K2.5M800K
Equity Issued (Net)-519.08M-307.36M-292.1M-17.68M-25.36M-92.07M-77.84M-72.38M-104.69M-304.92M6.27M-10.5M-126.89M-60.69M-35.65M011.24M650.49M18.45M42.28M11.01M7.96M5.13M2.11M2.33M4.09M20.76M2.68M939K700K31.1M
Dividends Paid-54.24M-54.24M00000000000000000000000000000
Share Repurchases-519.08M-307.36M-292.1M-17.68M-25.36M-99.99M-63.99M-74.45M-104.69M-60.97M0-20.82M-126.89M-86.03M-35.65M0000000000000000
Other Financing-30.76M-25.53M-23.47M20.61M8.11M-16.95M39.07M-61.28M-28.48M-30.76M-8.81M4.84M-5.61M-129K13.04M-2.39M3.78M6.7M-686K11.54M7.7M455K0003.6M0-803K147K00
Net Change in Cash7.53M175.45M-4.53M-62.59M-149.85M282.53M-31.23M-529.69M501.37M218.53M149.17M-102.66M62.36M-63.73M172.9M-607.27M2.85M492.24M-14.01M-83.04M238.66M-4.67M97.38M54.1M-11.57M32.45M9.14M5.8M2M2.3M-3.3M
Free Cash Flow410.54M453.28M506.38M296.65M565.93M432.47M188.03M55.96M208.73M162.37M247.68M200.02M190.96M140.26M116.8M123.39M126.84M147.64M115.08M26.2M66.13M77.51M41.18M44.5M-22.45M-43.98M-573K14.37M1.1M1.7M-5.6M
FCF Margin %19.56%21.69%25.6%15.09%26.43%19.21%10.05%3.67%13.9%11.45%18.51%15.61%14.2%10.77%9.31%10.55%11.66%14.62%12.89%4.03%14.2%19.46%10.82%12.66%-7.52%-16.67%-0.28%9.98%1%2.29%-10.33%
FCF Growth %-18.45%-10.49%70.7%-47.58%30.86%129.99%236.02%-73.19%28.55%-34.44%23.83%4.74%36.14%20.09%-5.35%-2.72%-14.09%28.29%339.29%-60.38%-14.69%88.23%-7.47%298.23%48.95%-7575.39%-103.99%1205.91%-35.29%130.36%-354.55%
FCF per Share1.962.182.321.362.541.920.830.250.890.701.080.880.820.600.500.540.550.720.590.150.450.540.290.31-0.16-0.31-0.000.110.010.01-0.05
FCF Conversion (FCF/Net Income)1.02x1.54x8.06x1.35x1.69x1.25x1.37x-7.98x1.89x7.10x4.25x2.44x2.47x3.75x1.89x2.55x1.74x1.58x1.94x1.69x1.44x1.47x1.10x1.49x1.59x1.69x1.85x1.88x0.88x0.97x0.77x
Interest Paid0024.18M20.35M23.21M21.59M25.35M29.72M25.9M20.25M18.23M20.8M24.05M31M17.3M20.76M25.56M27.66M36.46M000000000000
Taxes Paid0015.68M82.41M120.48M102.08M42.57M41.47M29.32M40.5M22.67M34.44M12.54M14.52M61.59M41.49M33.78M36M39.48M000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Diagnostic market share erosion

Earnings Quality Remains Consistently High

According to recent financial disclosures, QIAGEN consistently generates operating cash flow significantly in excess of net income, with the OCF/NI ratio reaching 1.48 in 2026Q1, suggesting that the company's reported earnings are supported by robust cash generation despite ongoing volatility in bottom-line accounting metrics.

The persistent gap between net income and operating cash flow indicates that non-cash charges, such as amortization of acquired intangibles, continue to depress reported earnings while cash-generative operations remain intact. Investors should monitor this divergence as it confirms that the core business model remains highly cash-productive even when accounting-based net income appears suppressed.

Free Cash Flow Margin Compression

As reported in quarterly statements, QIAGEN's free cash flow margin has trended downward to 10.9% in 2026Q1, a notable contraction from the 27.5% peak observed in 2024Q3, reflecting a combination of moderating cash inflows and sustained capital intensity required to support the company's five growth pillars.

This trajectory suggests that the company is entering a phase where capital requirements are rising relative to cash generation, potentially limiting the flexibility of its capital allocation strategy. The decline in FCF margins warrants further investigation into whether this is a temporary investment cycle or a structural shift in the cost of maintaining its diagnostic platform.

Capital Intensity Reflects Platform Investment

Based on the provided financial data, QIAGEN's capital expenditure as a percentage of revenue reached 9.8% in 2026Q1, indicating that the company continues to prioritize significant investment in its automated instrument base to secure long-term, high-margin consumable pull-through revenue across its global diagnostic and research segments.

The elevated capex levels appear to be a strategic choice to defend the company's installed base against competitors. While this spending is necessary to maintain the 'razor-blade' model, it effectively caps the near-term free cash flow available for shareholder returns or aggressive M&A activity.

Aggressive Capital Allocation Strategy

As evidenced by recent filings, QIAGEN has shifted its capital deployment focus toward significant share repurchases, with $496.7 million utilized in 2026Q1 alone, which appears to be a deliberate effort to manage share count despite the simultaneous pressure on free cash flow generation and margin performance.

This level of buyback activity suggests management's confidence in the long-term value of the business, yet it may also indicate a lack of immediate, high-return acquisition targets. Investors should monitor whether this aggressive return of capital remains sustainable if free cash flow margins continue to face downward pressure.

QGEN — Frequently Asked Questions

Quick answers to the most common questions about buying QGEN stock.

How much cash does Qiagen N.V. (QGEN) generate from operations?

Qiagen N.V. (QGEN) generated $654.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Qiagen N.V.'s free cash flow?

Qiagen N.V. (QGEN) generated $453.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Qiagen N.V.'s capital expenditure (CapEx)?

Qiagen N.V. (QGEN) spent $207.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Qiagen N.V. distribute cash to shareholders?

In 2025, Qiagen N.V. (QGEN) returned $54.2M to shareholders via cash dividends and spent $307.4M on share repurchases. This shows the company's commitment to returning capital to its equity investors.